Editas Medicine announced it will present two posters on novel gene editing therapies at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress in Hamburg on October 28, 2026. The presentations focus on targeted lipid nanoparticle delivery for CAR-T cell generation and a GMP-ready manufacturing platform. Additionally, Editas management will participate in the Guggenheim Healthcare Innovation Conference in November, offering investors insights into their progress. These events highlight Editas' ongoing development of transformative gene editing medicines for serious diseases.
Editas Medicine's upcoming presentations and conference participation provide context for readers following gene editing developments. For readers following the health sector, here is Pluang's market snapshot as of Oct 14, 2026 19:01 WIB: out of 150 priced US health stocks, 105 rose and 40 fell. Notable movers include DGX at USD 227.06 with a -1.52% change and 100% buy order activity, AVTR at USD 15.78 with a +1.48% change, and BRKR at USD 55.38 with a -1.44% change.
CodeWall Ltd. has emerged from stealth with $4 million in pre-seed funding to develop AI-powered autonomous attack agents that simulate real-world cyberattacks on enterprises. These agents start from outside the network with no insider access, contin...
Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...
Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...
DMC Global Inc. will announce its financial results for the third quarter ending September 30, 2026, on October 27 after the stock market closes. The company will hold a conference call and webcast to discuss the results, providing investors with ins...
Radware introduced its Model Context Protocol (MCP) Server Protection solution to help organizations secure the integration layer where AI agents connect to enterprise applications and workflows. This new security tool provides visibility into MCP in...
